背景:颅内出血是抗凝治疗的严重且可能致命的后果。Idarucizumab用于达比加群治疗的颅内出血(ICH)患者,以逆转达比加群的抗凝作用。缺乏对这些患者现实生活中死亡率的系统评价。目标:对所有已发表的与达比加群相关的ICH病例进行了综述。我们旨在估计这些患者的住院死亡率。方法:我们搜索了PubMed和Scopus在2021年5月15日之前在idarucizumab/dabigatran治疗的患者中所有已发表的ICH病例。评估的结果是院内死亡率。结果:我们确定了6项符合条件的研究(病例系列),其中386例患者和54例单病例报告。在病例系列中,住院死亡率为11.4%,在病例报告中为9.7%。结论:我们的分析提供了关于idarucizumab/dabigatran治疗的ICH患者院内死亡率的临床相关定量数据,估计为9.7-11.4%。
Background: Intracranial hemorrhage is a severe and possibly fatal consequence of anticoagulation therapy. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran. Systematic review of real-life mortality in these patients is missing. Objectives: A review of all published dabigatran-related ICH cases treated with idarucizumab was performed. We aimed to estimate in-hospital mortality rate in these patients. Method: We searched PubMed and Scopus for all published cases of ICH in idarucizumab/dabigatran-treated patients until May 15, 2021. The assessed outcome was in-hospital mortality. Results: We identified six eligible studies (
case series) with 386 patients and 54 single
case reports. In-hospital mortality rate was 11.4% in the
case series and 9.7% in the
case reports. Conclusions: Our analysis provides clinically relevant quantitative data regarding in-hospital mortality in idarucizumab/dabigatran-treated patients with ICH, which is estimated to be 9.7-11.4%.